Data obtained from public sources. Data sent for review to country expert(s), although not all data has been reviewed by country experts.
For questions and feedback write an email to ecan@goeg.at
Last Update: November 12, 2024
COUNTRY INFORMATION – IMPLEMENTATION
AUSTRIA
In Austria, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. There is also no certification or quality accreditation to assess the reliability of digital tools.
BELGIUM
In Belgium, there are public or commercial websites (such as mHealth Belgium) or other resources that are recommended to cancer patients or the general population. There are also certifications or quality accreditations to assess the reliability of digital tools (e.g. CE certification).
BULGARIA
In Bulgaria, there are public or commercial websites like еЗдраве which, together with non-governmental and commercial e-resources, provide information to the general population and cancer patients. However, there are no certifications or quality accreditations to assess the reliability of digital tools.
CROATIA
In Croatia, there are public or commercial websites (such as HZZO) or other resources that are recommended to cancer patients or the general population. There is no information about certifications or quality accreditations to assess the reliability of digital tools.
CYPRUS
In Cyprus, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. There is also no certification or quality accreditation to assess the reliability of digital tools.
CZECH REPUBLIC
The Czech Republic does not provide information about websites or other resources recommended to cancer patients or the general population. Information on certifications or quality accreditations to assess the reliability of digital tools is also not available.
DENMARK
In Denmark, there are public or commercial websites or other resources (such as Min Læge) that are recommended to cancer patients or the general population. There are also certifications or quality accreditations under development to assess the reliability of digital tools.
ESTONIA
In Estonia, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. However, there are certifications or quality accreditations to assess the reliability of digital tools (e.g. Digilahenduste teejuht)
FINLAND
In Finland, there are public or commercial websites or other resources (such as Noona) that are recommended to cancer patients or the general population. There are also certifications or quality accreditations to assess the reliability of digital tools (e.g. CEN ISO/TS 82304-2).
FRANCE
In France, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. However, there are certifications or quality accreditations to assess the reliability of digital tools (e.g. CE certification).
GERMANY
In Germany, there are public or commercial websites (such as Telehealth.de) or other resources that are recommended to cancer patients or the general population. There are also certifications or quality accreditations to assess the reliability of digital tools (e.g. Medizinproduktegesetz).
GREECE
Greece does not provide information about websites or other resources recommended to cancer patients or the general population. Information on certifications or quality accreditations to assess the reliability of digital tools is also not available.
HUNGARY
In Hungary, there are public or commercial websites (such as daganatok.hu and hospice.hu) or other resources that are recommended to cancer patients or the general population. Certifications or quality accreditations to assess the reliability of digital tools are planned or in development.
IRELAND
In Ireland, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. There is also no certification or quality accreditation to assess the reliability of digital tools.
ITALY
In Italy, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. Information on certifications or quality accreditations to assess the reliability of digital tools is not available.
LATVIA
In Latvia, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. Information on certifications or quality accreditations to assess the reliability of digital tools is not available.
LITHUANIA
In Lithuania, there are public or commercial websites or other resources that are recommended to cancer patients or the general population. There is no certification or quality accreditation to assess the reliability of digital tools.
LUXEMBOURG
In Luxembourg, there are public or commercial websites (such as eSanté) or other resources that are recommended to cancer patients or the general population. There is no information about certifications or quality accreditations to assess the reliability of digital tools.
MALTA
In Malta, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. However, information leaflets are publicly available online. Information on certifications or quality accreditations to assess the reliability of digital tools is not available.
NETHERLANDS
In the Netherlands, there are public or commercial websites (such as kanker.nl) or other resources that are recommended to cancer patients or the general population. There are also certifications or quality accreditations to assess the reliability of digital tools (e.g. ISO 82304-2).
NORWAY
Norway does not provide information about websites or other resources recommended to cancer patients or the general population. There is no specific certification for cancer eHealth tools, however a general system for CE-marking of medical equipment, also eHealth related, is in place.
POLAND
In Poland, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. There is also no certification or quality accreditation to assess the reliability of digital tools.
PORTUGAL
In Portugal, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. However, there are certifications or quality accreditations to assess the reliability of digital tools established by INFARMED.
ROMANIA
In Romania, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. There is also no certification or quality accreditation to assess the reliability of digital tools.
SLOVAK REPUBLIC
In Slovakia, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. There is also no certification or quality accreditation to assess the reliability of digital tools.
SLOVENIA
In Slovenia, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. Information on certifications or quality accreditations to assess the reliability of digital tools is not available.
SPAIN
In Spain, there are public or commercial websites (such as redescuelassalud.es) or other resources that are recommended to cancer patients or the general population. There is no information about certifications or quality accreditations to assess the reliability of digital tools.
SWEDEN
In Sweden, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. However, there are certifications or quality accreditations to assess the reliability of digital tools (e.g. CE certification).
SWITZERLAND
In Switzerland, there are no public or commercial websites or other resources that are recommended to cancer patients or the general population. However, there are certifications or quality accreditations to assess the reliability of digital tools stablished by eHealth Suisse.
OUR X
@ecan_ja @sciensano @iMedPhysAUTH @NIO_PIB I am pleased that the results of our work package will be presented to the public [digital + cancer] health crowd tomorrow.
See you there!!
@goeg_at @euphadhai @PHMRsection @EU_Health @ecan_ja @ECHoS_CMH
💬 "According to #cancer patients and policy experts, #telemedicine is seen as a useful complementary tool, but not as a replacement for in-person services."
@SchmittTugce, presenting the results of the @ecan_ja foresight study at @EPHconference. #EPH2024 https://ecanja.eu/
📢 Join us at the #EPH2024!
🗓️ Date: Thursday, November 14th
⏰ Time: 11:45 – 12:45
📍 Location: Lisbon, Portugal
➕ info: https://ecanja.eu/event/17th-european-public-health-conference/
#publichealth #EU4Health #HealthUnion
CONTACT
In the contact form you can indicate why you are contacting us by choosing one of the issues of the dropdown list.